Initial testing (stage 1) of SGI-1776, a PIM1 kinase inhibitor, by the pediatric preclinical testing program

Vandana Batra, John M. Maris, Min H. Kang, C. Patrick Reynolds, Peter J. Houghton, Denise Alexander, E. Anders Kolb, Richard Gorlick, Stephen T. Keir, Hernan Carol, Richard Lock, Catherine A. Billups, Malcolm A. Smith

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

The PIM kinase inhibitor, SGI-1776, was tested against the PPTP in vitro (1.0nM-10μM) and in vivo panels (148mg/kg daily×5 days for 3 weeks). SGI-1776 exhibited cytotoxic activity in vitro with a median relative IC 50 of 3.1μM. SGI-1776 induced significant differences in EFS distribution in vivo in 9 of 31 solid tumor xenografts and in 1 of 8 of the evaluable ALL xenografts. SGI-1776 induced tumor growth inhibition meeting criteria for intermediate EFS T/C activity in 1 of 39 evaluable models. In contrast, SGI-1776 induced complete responses of subcutaneous MV4;11 (B myeloid leukemia). Pediatr Blood Cancer 2012;59:749-752.

Original languageEnglish (US)
Pages (from-to)749-752
Number of pages4
JournalPediatric Blood and Cancer
Volume59
Issue number4
DOIs
StatePublished - Oct 2012

Fingerprint

Phosphotransferases
Pediatrics
Heterografts
Neoplasms
Myeloid Leukemia
SGI 1776
Growth
In Vitro Techniques

Keywords

  • Developmental therapeutics
  • Kinase inhibitors
  • Preclinical testing

ASJC Scopus subject areas

  • Oncology
  • Pediatrics, Perinatology, and Child Health
  • Hematology

Cite this

Batra, V., Maris, J. M., Kang, M. H., Reynolds, C. P., Houghton, P. J., Alexander, D., ... Smith, M. A. (2012). Initial testing (stage 1) of SGI-1776, a PIM1 kinase inhibitor, by the pediatric preclinical testing program. Pediatric Blood and Cancer, 59(4), 749-752. https://doi.org/10.1002/pbc.23364

Initial testing (stage 1) of SGI-1776, a PIM1 kinase inhibitor, by the pediatric preclinical testing program. / Batra, Vandana; Maris, John M.; Kang, Min H.; Reynolds, C. Patrick; Houghton, Peter J.; Alexander, Denise; Kolb, E. Anders; Gorlick, Richard; Keir, Stephen T.; Carol, Hernan; Lock, Richard; Billups, Catherine A.; Smith, Malcolm A.

In: Pediatric Blood and Cancer, Vol. 59, No. 4, 10.2012, p. 749-752.

Research output: Contribution to journalArticle

Batra, V, Maris, JM, Kang, MH, Reynolds, CP, Houghton, PJ, Alexander, D, Kolb, EA, Gorlick, R, Keir, ST, Carol, H, Lock, R, Billups, CA & Smith, MA 2012, 'Initial testing (stage 1) of SGI-1776, a PIM1 kinase inhibitor, by the pediatric preclinical testing program', Pediatric Blood and Cancer, vol. 59, no. 4, pp. 749-752. https://doi.org/10.1002/pbc.23364
Batra, Vandana ; Maris, John M. ; Kang, Min H. ; Reynolds, C. Patrick ; Houghton, Peter J. ; Alexander, Denise ; Kolb, E. Anders ; Gorlick, Richard ; Keir, Stephen T. ; Carol, Hernan ; Lock, Richard ; Billups, Catherine A. ; Smith, Malcolm A. / Initial testing (stage 1) of SGI-1776, a PIM1 kinase inhibitor, by the pediatric preclinical testing program. In: Pediatric Blood and Cancer. 2012 ; Vol. 59, No. 4. pp. 749-752.
@article{13f0fa87d3304c69b7bcb25d409d0a90,
title = "Initial testing (stage 1) of SGI-1776, a PIM1 kinase inhibitor, by the pediatric preclinical testing program",
abstract = "The PIM kinase inhibitor, SGI-1776, was tested against the PPTP in vitro (1.0nM-10μM) and in vivo panels (148mg/kg daily×5 days for 3 weeks). SGI-1776 exhibited cytotoxic activity in vitro with a median relative IC 50 of 3.1μM. SGI-1776 induced significant differences in EFS distribution in vivo in 9 of 31 solid tumor xenografts and in 1 of 8 of the evaluable ALL xenografts. SGI-1776 induced tumor growth inhibition meeting criteria for intermediate EFS T/C activity in 1 of 39 evaluable models. In contrast, SGI-1776 induced complete responses of subcutaneous MV4;11 (B myeloid leukemia). Pediatr Blood Cancer 2012;59:749-752.",
keywords = "Developmental therapeutics, Kinase inhibitors, Preclinical testing",
author = "Vandana Batra and Maris, {John M.} and Kang, {Min H.} and Reynolds, {C. Patrick} and Houghton, {Peter J.} and Denise Alexander and Kolb, {E. Anders} and Richard Gorlick and Keir, {Stephen T.} and Hernan Carol and Richard Lock and Billups, {Catherine A.} and Smith, {Malcolm A.}",
year = "2012",
month = "10",
doi = "10.1002/pbc.23364",
language = "English (US)",
volume = "59",
pages = "749--752",
journal = "Pediatric Blood and Cancer",
issn = "1545-5009",
publisher = "Wiley-Liss Inc.",
number = "4",

}

TY - JOUR

T1 - Initial testing (stage 1) of SGI-1776, a PIM1 kinase inhibitor, by the pediatric preclinical testing program

AU - Batra, Vandana

AU - Maris, John M.

AU - Kang, Min H.

AU - Reynolds, C. Patrick

AU - Houghton, Peter J.

AU - Alexander, Denise

AU - Kolb, E. Anders

AU - Gorlick, Richard

AU - Keir, Stephen T.

AU - Carol, Hernan

AU - Lock, Richard

AU - Billups, Catherine A.

AU - Smith, Malcolm A.

PY - 2012/10

Y1 - 2012/10

N2 - The PIM kinase inhibitor, SGI-1776, was tested against the PPTP in vitro (1.0nM-10μM) and in vivo panels (148mg/kg daily×5 days for 3 weeks). SGI-1776 exhibited cytotoxic activity in vitro with a median relative IC 50 of 3.1μM. SGI-1776 induced significant differences in EFS distribution in vivo in 9 of 31 solid tumor xenografts and in 1 of 8 of the evaluable ALL xenografts. SGI-1776 induced tumor growth inhibition meeting criteria for intermediate EFS T/C activity in 1 of 39 evaluable models. In contrast, SGI-1776 induced complete responses of subcutaneous MV4;11 (B myeloid leukemia). Pediatr Blood Cancer 2012;59:749-752.

AB - The PIM kinase inhibitor, SGI-1776, was tested against the PPTP in vitro (1.0nM-10μM) and in vivo panels (148mg/kg daily×5 days for 3 weeks). SGI-1776 exhibited cytotoxic activity in vitro with a median relative IC 50 of 3.1μM. SGI-1776 induced significant differences in EFS distribution in vivo in 9 of 31 solid tumor xenografts and in 1 of 8 of the evaluable ALL xenografts. SGI-1776 induced tumor growth inhibition meeting criteria for intermediate EFS T/C activity in 1 of 39 evaluable models. In contrast, SGI-1776 induced complete responses of subcutaneous MV4;11 (B myeloid leukemia). Pediatr Blood Cancer 2012;59:749-752.

KW - Developmental therapeutics

KW - Kinase inhibitors

KW - Preclinical testing

UR - http://www.scopus.com/inward/record.url?scp=84864928386&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84864928386&partnerID=8YFLogxK

U2 - 10.1002/pbc.23364

DO - 10.1002/pbc.23364

M3 - Article

C2 - 22052829

AN - SCOPUS:84864928386

VL - 59

SP - 749

EP - 752

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

SN - 1545-5009

IS - 4

ER -